Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP3 | P08254 | 14/20 | 0.48 |
| ▸ | MMP1 | P03956 | 10/20 | 0.48 |
| ▸ | MMP2 | P08253 | 6/20 | 0.48 |
| ▸ | MMP13 | P45452 | 2/20 | 0.48 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.48 |
| ▸ | TNF | P01375 | 1/20 | 0.48 |
| ▸ | FCER2 | P06734 | 2/20 | 0.42 |
| ▸ | MMP9 | P14780 | 1/20 | 0.42 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.38 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6417772 | 1.00 | MMP3 (0.48) | MMP3MMP1MMP2MMP13ADAM17 | |
| SCHEMBL6413230 | 0.88 | MMP3 (0.45) | MMP3MMP1MMP2ADAM17TNF | |
| SCHEMBL8665728 | 0.87 | MMP3 (0.44) | MMP3MMP1MMP2FCER2MMP9 | |
| SCHEMBL8667836 | 0.87 | FCER2 (0.48) | MMP3MMP1MMP2FCER2MMP9 | |
| SCHEMBL8664100 | 0.87 | MMP2 (0.49) | MMP3MMP1MMP2ADAM17TNF | |
| SCHEMBL6418840 | 0.85 | FCER2 (0.40) | MMP3MMP1MMP2FCER2MMP9 | |
| SCHEMBL6412000 | 0.85 | FCER2 (0.44) | MMP3MMP1MMP2FCER2MMP9 | |
| SCHEMBL8663575 | 0.80 | MMP3 (0.46) | MMP3MMP1MMP2MMP13ADAM17 | |
| SCHEMBL8668754 | 0.78 | MMP3 (0.58) | MMP3MMP1MMP2MMP13ADAM17 | |
| SCHEMBL8665565 | 0.77 | MMP3 (0.56) | MMP3MMP1MMP2MMP13ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098662-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2001-05-16 | — | — | EP | disclosed |
| WO-2000004892-A2 | COADMINISTRATION OF ACAT AND MMP INHIBITORS FOR THE TREATMENT OF ATHEROSCLEROTIC LESIONS | WARNER-LAMBERT COMPANY (US) | 2000-02-03 | — | — | WO | disclosed |